TOLREMO Therapeutics AG (“TOLREMO”) is a Swiss biotechnology company spun out of ETH Zurich in 2017, built on cutting-edge science and guided by pioneering real-world medicine to tackle the critical challenge of cancer drug resistance. The company has developed a broad and differentiated cancer drug resistance platform that offers a unique entry point into a major clinical problem. Through two parallel R&D programs, TOLREMO is advancing resistance-breaking add-on therapies designed to extend the therapeutic benefit of oncogene-targeting cancer drugs through its Adaptive Drug Resistance Program and anti-angiogenic cancer drugs through its Hypoxia-Driven Drug Resistance Program. TOLREMO’s innovative platform has the potential to catalyze a new wave of potent resistance-breaking molecules that can meaningfully extend and improve the lives of patients suffering from cancer.